MS and Demyelinating Disorders

The assistant professor at Hunter College talked about how to effectively diagnose and treat multiple sclerosis through localization and active listening of the patient's history and symptoms. [WATCH TIME: 7 minutes]

The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Intravenous methylprednisolone combined with plasma exchange/immunoadsorption achieved better and continuous improvement than IVMP alone

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on multiple system atrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 12, 2024.

In the final episode, Negroski gave closing thoughts on some of the major unmet needs in research regarding aging in MS, as well as some of the unanswered questions clinicians are still trying to figure out.

Donald Negroski, MD, gave an overview of a study that highlighted an accelerated biologic aging clock among patients with pediatric-onset MS.

As part of our monthly clinician spotlight, NeurologyLive® highlighted multiple sclerosis expert Marisa McGinley, DO, the staff neurologist at Cleveland Clinic’s Mellen Center for MS.

Catch up on any of the neurology news headlines you may have missed over the course of June 2024, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on headache and nerve decompression surgery.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 5, 2024.

Bryant Robinson, senior manager of government relations at the National MS Society, discussed how telehealth access has become vital for patients with multiple sclerosis who often lack nearby specialist care.

After 48 weeks of continued treatment, those in the high-dose frexalimab group showed a 41% reduction in neurofilament light.

Data from the large-scale, phase 3 OCARINA 2 trial was the basis for the approval.

Negroski detailed a real-world analysis on cladribine, an FDA-approved DMT, in an aging population of MS, and the recent increase in research for older populations with the disease.

In this episode, Negroski gave insight on the impact of health care-related social determinants of health, their impact on brain structure and aging in MS, and where efforts should be directed towards going forward.

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy/Dravet syndrome.

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed how combining advanced therapies with lifestyle modifications can improve outcomes and slow disease progression in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 28, 2024.

In this segment, Negroski comments on the realism behind wearing off effect of treatments, specifically ocrelizumab, and how clinicians may work around some of these issues.

Here's some of what is coming soon to NeurologyLive® this week.